{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T23:13:39Z","timestamp":1722467619686},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Natural Science Fund","award":["81700559"],"award-info":[{"award-number":["81700559"]}]},{"name":"the National Science and Technology Projects","award":["2017ZX10203201","2017ZX10202202"],"award-info":[{"award-number":["2017ZX10203201","2017ZX10202202"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The predictive effect of quantitative anti-hepatitis B core on double-negative HBV DNA and RNA remains unstudied. We observed dynamic changes in this measure in chronic hepatitis B patients receiving entecavir for 10\u00a0years, evaluating its predictive value for double-negative HBV DNA and RNA. Twenty-seven chronic hepatitis B patients treated with entecavir for 10\u00a0years were enrolled in this study. Liver function, quantitative anti-hepatitis B core, hepatitis B surface and e antigens, HBV DNA and RNA were measured at baseline and each follow-up. Virological response was defined as double-negative HBV DNA and RNA; serological response was defined as hepatitis B e antigen seroconversion. After antiviral therapy, quantitative anti-hepatitis B core showed an overall downward trend. Patients with virological response had significantly higher quantitative anti-hepatitis B core levels than those without virological response at baseline. Patients with serological response also had higher quantitative anti-hepatitis B core levels than those without serological response at baseline and week 24. Baseline quantitative anti-hepatitis B core level was the only independent predictor for virological and serological responses. Baseline quantitative anti-hepatitis B core level was powerfully predictive of double-negative HBV DNA and RNA in chronic hepatitis B patients receiving long-term entecavir therapy.<\/jats:p>","DOI":"10.1038\/s41598-021-92757-0","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T10:03:17Z","timestamp":1624874597000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10\u00a0years"],"prefix":"10.1038","volume":"11","author":[{"given":"Xi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaocui","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"92757_CR1","doi-asserted-by":"publisher","first-page":"324","DOI":"10.4103\/2347-5625.195896","volume":"3","author":"H Lee","year":"2016","unstructured":"Lee, H., Fawcett, J., Kim, D. & Yang, J. H. Correlates of hepatitis B virus-related stigmatization experienced by Asians: A scoping review of literature. Asia Pac. J. Oncol. Nurs. 3, 324\u2013334 (2016).","journal-title":"Asia Pac. J. Oncol. Nurs."},{"key":"92757_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin, S. K. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol. Int. 10, 1\u201398 (2016).","journal-title":"Hepatol. Int."},{"key":"92757_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. European Association for the Study of the, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370\u2013398 (2017).","journal-title":"J. Hepatol."},{"key":"92757_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault, N. A. et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63, 261\u2013283 (2016).","journal-title":"Hepatology"},{"key":"92757_CR5","unstructured":"C. M. A. Chinese Society of Hepatology, C. M. A. Chinese Society of Infectious Diseases. The guideline of prevention and treatment for chronic hepatitis B: A 2015 update. Zhonghua Gan Zang Bing Za Zhi 23, 888\u2013905 (2015)."},{"key":"92757_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00535-006-1856-4","volume":"41","author":"A Rokuhara","year":"2006","unstructured":"Rokuhara, A. et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J. Gastroenterol. 41, 785\u2013790 (2006).","journal-title":"J. Gastroenterol."},{"key":"92757_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jcv.2017.12.016","volume":"99\u2013100","author":"H Huang","year":"2018","unstructured":"Huang, H. et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals. J. Clin. Virol. 99\u2013100, 71\u201378 (2018).","journal-title":"J. Clin. Virol."},{"key":"92757_CR8","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jhep.2016.10.034","volume":"66","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. Reply to: \u201cSerum HBV pgRNA as a clinical marker for cccDNA activity\u201d: Consistent loss of serum HBV RNA might predict the \u201cpara-functional cure\u201d of chronic hepatitis B. J. Hepatol. 66, 462\u2013463 (2017).","journal-title":"J. Hepatol."},{"key":"92757_CR9","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jhep.2016.09.028","volume":"66","author":"K Giersch","year":"2017","unstructured":"Giersch, K., Allweiss, L., Volz, T., Dandri, M. & Lutgehetmann, M. Serum HBV pgRNA as a clinical marker for cccDNA activity. J. Hepatol. 66, 460\u2013462 (2017).","journal-title":"J. Hepatol."},{"key":"92757_CR10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.cgh.2019.07.046","volume":"18","author":"R Fan","year":"2020","unstructured":"Fan, R. et al. Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy. Clin. Gastroenterol. Hepatol. 18, 719\u2013727 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"92757_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cmi.2014.10.002","volume":"21","author":"LW Song","year":"2015","unstructured":"Song, L. W. et al. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. Clin. Microbiol. Infect. 21, 197\u2013203 (2015).","journal-title":"Clin. Microbiol. Infect."},{"key":"92757_CR12","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1053\/j.gastro.2008.02.017","volume":"134","author":"A Zerbini","year":"2008","unstructured":"Zerbini, A. et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 134, 1470\u20131481 (2008).","journal-title":"Gastroenterology"},{"key":"92757_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/gutjnl-2012-302656","volume":"62","author":"Q Yuan","year":"2013","unstructured":"Yuan, Q. et al. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut 62, 182\u2013184 (2013).","journal-title":"Gut"},{"key":"92757_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.7150\/thno.10636","volume":"5","author":"FQ Hou","year":"2015","unstructured":"Hou, F. Q. et al. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics 5, 218\u2013226 (2015).","journal-title":"Theranostics"},{"key":"92757_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/gutjnl-2014-308546","volume":"65","author":"R Fan","year":"2016","unstructured":"Fan, R. et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut 65, 313\u2013320 (2016).","journal-title":"Gut"},{"key":"92757_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/jvh.12626","volume":"24","author":"JH Xu","year":"2017","unstructured":"Xu, J. H. et al. Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir. J. Viral Hepat. 24, 148\u2013154 (2017).","journal-title":"J. Viral Hepat."},{"key":"92757_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2147\/IDR.S163038","volume":"11","author":"S Cai","year":"2018","unstructured":"Cai, S., Li, Z., Yu, T., Xia, M. & Peng, J. Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs. Infect. Drug Resist. 11, 469\u2013477 (2018).","journal-title":"Infect. Drug Resist."},{"key":"92757_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10238-019-00603-5","volume":"20","author":"X Fu","year":"2020","unstructured":"Fu, X., Lou, H., Chen, F., Gao, X. & Lin, Z. Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels. Clin. Exp. Med. 20, 241\u2013248 (2020).","journal-title":"Clin. Exp. Med."},{"key":"92757_CR19","doi-asserted-by":"publisher","first-page":"e4422","DOI":"10.1097\/MD.0000000000004422","volume":"95","author":"MR Li","year":"2016","unstructured":"Li, M. R. et al. Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-naive chronic hepatitis B patients. Medicine 95, e4422 (2016).","journal-title":"Medicine"},{"key":"92757_CR20","doi-asserted-by":"publisher","first-page":"11063","DOI":"10.18632\/oncotarget.14323","volume":"8","author":"MR Li","year":"2017","unstructured":"Li, M. R. et al. Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naive patients with chronic hepatitis B. Oncotarget 8, 11063\u201311070 (2017).","journal-title":"Oncotarget"},{"key":"92757_CR21","doi-asserted-by":"publisher","first-page":"114985","DOI":"10.1016\/j.diagmicrobio.2020.114985","volume":"96","author":"GP Caviglia","year":"2020","unstructured":"Caviglia, G. P. et al. Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. Diagn. Microbiol. Infect. Dis. 96, 114985 (2020).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"92757_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijid.2020.07.031","volume":"99","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks. Int. J. Infect. Dis. 99, 171\u2013178 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"92757_CR23","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/infdis\/jiy270","volume":"218","author":"F van B\u00f6mmel","year":"2018","unstructured":"van B\u00f6mmel, F. et al. Serum HBV RNA as a predictor of peginterferon alfa-2a response in patients with HBeAg-positive chronic hepatitis B. J. Infect. Dis. 218, 1066\u20131074 (2018).","journal-title":"J. Infect. Dis."},{"key":"92757_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jhep.2010.10.016","volume":"55","author":"B Oliviero","year":"2011","unstructured":"Oliviero, B. et al. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. J. Hepatol. 55, 53\u201360 (2011).","journal-title":"J. Hepatol."},{"key":"92757_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/jmv.24067","volume":"87","author":"AK Zgair","year":"2015","unstructured":"Zgair, A. K., Ghafil, J. A. & Al-Sayidi, R. H. Direct role of antibody-secreting B cells in the severity of chronic hepatitis B. J. Med. Virol. 87, 407\u2013416 (2015).","journal-title":"J. Med. Virol."},{"key":"92757_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/JCM.39.1.362-364.2001","volume":"39","author":"H Naito","year":"2001","unstructured":"Naito, H., Hayashi, S. & Abe, K. Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers. J. Clin. Microbiol. 39, 362\u2013364 (2001).","journal-title":"J. Clin. Microbiol."},{"key":"92757_CR27","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1128\/CVI.00457-09","volume":"17","author":"A Li","year":"2010","unstructured":"Li, A. et al. Novel double-antigen sandwich immunoassay for human hepatitis B core antibody. Clin. Vaccine Immunol. 17, 464\u2013469 (2010).","journal-title":"Clin. Vaccine Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92757-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92757-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92757-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T10:21:02Z","timestamp":1670062862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92757-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["92757"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-92757-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]},"assertion":[{"value":"21 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13389"}}